Opinion

Video

Biomarkers for IgAN

Key Takeaways

  • Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
  • Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
SHOW MORE

Panelists discuss potential biomarkers and clinical indicators that can aid in predicting disease outcomes for individual patients with IgA nephropathy.

Can you describe any biomarkers or clinical indicators that may help in predicting disease outcomes in individual patients?

Related Videos
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Christian T. Ruff, MD, MPH: Abelacimab Cuts Bleeding Risk Versus Rivaroxaban| Image Credit: Brigham & Women's Hospital
Barry A. Borlaug, MD: Impact of Tirzepatide on Cardiorenal End-Organ Damage | Image Credit: Mayo Clinicn HFpEF
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.